ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Dianthus Therapeutics Inc

Dianthus Therapeutics Inc (DNTH)

17.44
0.17
(0.98%)
17.44
0.01
(0.06%)

Professional-Grade Tools, for Individual Investors.

Premium

Key stats and details

Current Price
17.44
Bid
16.87
Ask
20.00
Volume
231,928
16.98 Day's Range 17.98
13.365 52 Week Range 31.97
Market Cap
Previous Close
17.27
Open
17.15
Last Trade Time
Financial Volume
$ 4,072,199
VWAP
17.558
Average Volume (3m)
320,995
Shares Outstanding
32,159,982
Dividend Yield
-
PE Ratio
-6.60
Earnings Per Share (EPS)
-2.64
Revenue
6.24M
Net Profit
-84.97M

About Dianthus Therapeutics Inc

Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to advancing antibody complement therapeutics to treat severe autoimmune diseases. The Company is dedicated to designing and delivering monoclonal antibodies with improved selectivity and potency. The Company has initiat... Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to advancing antibody complement therapeutics to treat severe autoimmune diseases. The Company is dedicated to designing and delivering monoclonal antibodies with improved selectivity and potency. The Company has initiated a Phase 2 trial of DNTH103, a potential active C1s inhibitor, in generalized Myasthenia Gravis and plans to initiate additional Phase 2 trials in other neuromuscular indications, including Multifocal Motor Neuropathy and Chronic Inflammatory Demyelinating Polyneuropathy. Its product candidate, DNTH103, is a clinical-stage, highly potent, highly selective and fully human monoclonal immunoglobulin G4 with picomolar binding affinity that is designed to selectively bind only to the active form of the C1s complement protein. DNTH103 is engineered with YTE half-life extension technology, a specific three amino acid change in the Fc domain, and has a pharmacokinetic (PK) profile. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Wilmington, Delaware, USA
Founded
-
Dianthus Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker DNTH. The last closing price for Dianthus Therapeutics was $17.27. Over the last year, Dianthus Therapeutics shares have traded in a share price range of $ 13.365 to $ 31.97.

Dianthus Therapeutics currently has 32,159,982 shares outstanding. The market capitalization of Dianthus Therapeutics is $555.40 million. Dianthus Therapeutics has a price to earnings ratio (PE ratio) of -6.60.

DNTH Latest News

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-1.43-7.578166401718.8719.5817.1826258218.44838384CS
4-1.45-7.676019057718.8919.5816.9126870118.22851349CS
12-0.71-3.9118457300318.1523.6913.36532099518.44518472CS
26-6.71-27.78467908924.1528.6513.36529945920.33572758CS
52-7.83-30.985358132225.2731.9713.36527711423.31685441CS
1567.0467.692307692310.433.776.5819894923.19158296CS
2607.0467.692307692310.433.776.5819894923.19158296CS

DNTH - Frequently Asked Questions (FAQ)

What is the current Dianthus Therapeutics share price?
The current share price of Dianthus Therapeutics is $ 17.44
How many Dianthus Therapeutics shares are in issue?
Dianthus Therapeutics has 32,159,982 shares in issue
What is the market cap of Dianthus Therapeutics?
The market capitalisation of Dianthus Therapeutics is USD 555.4M
What is the 1 year trading range for Dianthus Therapeutics share price?
Dianthus Therapeutics has traded in the range of $ 13.365 to $ 31.97 during the past year
What is the PE ratio of Dianthus Therapeutics?
The price to earnings ratio of Dianthus Therapeutics is -6.6
What is the cash to sales ratio of Dianthus Therapeutics?
The cash to sales ratio of Dianthus Therapeutics is 89.89
What is the reporting currency for Dianthus Therapeutics?
Dianthus Therapeutics reports financial results in USD
What is the latest annual turnover for Dianthus Therapeutics?
The latest annual turnover of Dianthus Therapeutics is USD 6.24M
What is the latest annual profit for Dianthus Therapeutics?
The latest annual profit of Dianthus Therapeutics is USD -84.97M
What is the registered address of Dianthus Therapeutics?
The registered address for Dianthus Therapeutics is 1209 ORANGE STREET, WILMINGTON, DELAWARE, 19801
What is the Dianthus Therapeutics website address?
The website address for Dianthus Therapeutics is www.magentatx.com
Which industry sector does Dianthus Therapeutics operate in?
Dianthus Therapeutics operates in the PHARMACEUTICAL PREPARATIONS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
NWGLNature Wood Group Ltd
$ 5.615
(142.03%)
5.98M
KWEKWESST Micro Systems Inc
$ 11.2296
(94.96%)
37.36M
PTLEPTL Ltd
$ 0.3656
(84.74%)
404.15M
APVOAptevo Therapeutics Inc
$ 5.01
(77.66%)
124.46M
MRINMarin Software Incorporated
$ 1.435
(68.82%)
50.06M
CBIOCrescent Biopharma Inc
$ 14.60
(-71.45%)
97.59k
CEROCERo Therapeutics Holdings Inc
$ 11.5501
(-41.75%)
3.03M
BMEABiomea Fusion Inc
$ 1.90
(-34.48%)
11.66M
PSTVPlus Therapeutics Inc
$ 0.2025
(-34.38%)
23.9M
CONIGraniteShares ETF Trust 2X Short COIN Daily ETF
$ 3.7198
(-32.49%)
21.46M
HCTIHealthcare Triangle Inc
$ 0.0265
(19.91%)
455.2M
PTLEPTL Ltd
$ 0.3656
(84.74%)
404.15M
GNLNGreenlane Holdings Inc
$ 0.01035
(-0.48%)
260.94M
NVDANVIDIA Corporation
$ 145.48
(0.94%)
161.48M
TSLLDirexion Daily TSLA Bull 2X Trust ETF
$ 12.365
(3.56%)
141.16M

Your Recent History

Delayed Upgrade Clock